Metabolic dysfunction‐associated liver disease predicts incident liver fibrosis in people with HIV mono‐infection: A cohort study
Authors:
- Juliana FittipaldiJFJuliana Fittipaldi
- Sandra W. CardosoSCSandra W. Cardoso
- Estevão Portela NunesENEstevão Portela Nunes
- Cristiane Fonseca De AlmeidaCACristiane Fonseca De Almeida
- Patricia Dias De BritoPBPatricia Dias De Brito
- Valdilea G. VelosoVVValdilea G. Veloso
- Beatriz GrinsztejnBGBeatriz Grinsztejn
- Hugo PerazzoHPHugo Perazzo
Open Access
- 23 July 2025
- journal article
- Published by Wiley in HIV Medicine
- Vol. 26 (10) , 1525-1539
Abstract
Introduction: Metabolic dysfunction‐associated liver disease (MASLD) might progress to cirrhosis. We aimed to evaluate the association of MASLD with the risk of developing clinically significant fibrosis (CSF) in people living with HIV (PLWH). Methods: PLWH have been followed up since 2015 in the PROSPEC‐HIV cohort (NCT02542020) with questionnaires, blood samples, and transient elastography (TE) on the same day. Participants with viral hepatitis, who were c‐ART naïve, those with CSF at baseline or unreliable TE examinations and who lost follow‐up were excluded. Liver steatosis and fibrosis were assessed by TE‐Controlled Attenuation Parameter (CAP) and TE‐liver stiffness measurement (LSM), respectively. MASLD was defined as the presence of steatosis (CAP ≥263 dB/m) at baseline with at least one cardiometabolic risk factor without hazardous alcohol intake [Alcohol Use Disorders Identification Test (AUDIT) score 2 and 17.8% with MASLD) were included. During a median follow‐up of 7.4 (IQR, 6.0–8.3) years, 11.8% ( n = 36) participants developed CSF. The cumulative incidence of CSF at the 8th year was higher in PLWH with MASLD than in those without (30.1% [95% CI, 18.0–47.6] vs. 8.8% [95% CI, 5.4–14.2], p < 0.001). MASLD at baseline was significantly associated with the incidence of CSF in a multivariate Cox model (adjusted hazard ratio [aHR] = 2.92 [95% CI, 1.40–6.09]). Conclusion: MASLD increased the risk of liver fibrosis in people with HIV mono‐infection under c‐ART.Keywords
Funding Information
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (E‐26/201.351/2021)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (445957/2020‐4)
This publication has 40 references indexed in Scilit:
- Metabolic causes of liver disease among adults living with HIV from low‐ and middle‐income countries: a cross‐sectional studyJournal of the International AIDS Society, 2024
- Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017–2020Clinical Gastroenterology and Hepatology, 2023
- The WHO has declared the end of pandemic phase of COVID‐19: Way to come back in the normal lifeHealth Science Reports, 2023
- Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2023
- Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)eClinicalMedicine, 2021
- Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency VirusClinical Gastroenterology and Hepatology, 2020
- Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono‐infection under long‐term combined antiretroviral therapyJournal of the International AIDS Society, 2018
- Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosisJournal of Hepatology, 2017
- The Rotterdam Study: 2018 update on objectives, design and main resultsEuropean Journal of Epidemiology, 2017
- Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam studyJournal of Hepatology, 2017